Hyperglycemia Management in Hospitalized Patients

Insulin Administration Protocol

• The American Diabetes Association recommends regular insulin administration subcutaneously every 4-6 hours as needed for blood glucose correction in hospitalized patients 1, 2
• For non-DKA hyperglycemia in hospitalized patients, regular insulin can be administered subcutaneously every 6 hours for hyperglycemia correction 1, 3
• Rapid-acting insulin analogs can be administered every 4 hours as an alternative for non-DKA hyperglycemia in hospitalized patients 1
• In adult patients who are NPO, supplemental subcutaneous regular insulin can be given in 5-unit increments for every 50 mg/dl increase in blood glucose above 150 mg/dl, up to 20 units for blood glucose of 300 mg/dl 4, 5

Insulin Administration for Specific Patient Populations

• For patients on continuous enteral feedings, regular insulin every 6 hours or rapid-acting insulin every 4 hours can be used for hyperglycemia management 1, 3
• For patients on bolus enteral feedings, regular insulin every 6 hours or rapid-acting insulin every 4 hours can be used for hyperglycemia management 1, 3
• For patients on parenteral feedings, regular insulin every 6 hours or rapid-acting insulin every 4 hours can be used for hyperglycemia management 1, 3

DKA Management

• For mild DKA, an initial "priming" dose of regular insulin of 0.4–0.6 units/kg body weight can be given, followed by 0.1 unit/kg regular insulin subcutaneously or intramuscularly every hour 4, 5, 6
• For moderate to severe DKA, continuous intravenous insulin infusion is the preferred treatment, with an initial IV bolus of regular insulin at 0.15 units/kg body weight, followed by continuous infusion at 0.1 unit/kg/hour 6, 7

Monitoring and Adjustments

• Blood should be drawn every 2-4 hours for determination of serum electrolytes, glucose, blood urea nitrogen, creatinine, osmolality, and venous pH (for DKA) 4, 5, 8
• Criteria for resolution of DKA includes glucose <200 mg/dl, serum bicarbonate ≥18 mEq/l, and venous pH of ≥7.3 4, 5

Transition to Maintenance Therapy

• When the patient is able to eat, transition to a multiple-dose schedule using a combination of short/rapid-acting and intermediate/long-acting insulin can be considered 4, 5
• A structured discharge plan tailored to the individual patient may reduce length of hospital stay and readmission rates 2, 9

Duration of Regular Insulin in Insulin Drip

Pharmacokinetics of IV Regular Insulin

• The effects of regular insulin administered via continuous intravenous infusion cease rapidly once the infusion is stopped, typically within 10-20 minutes, due to insulin's short plasma half-life of approximately 4-6 minutes, according to the American Academy of Family Physicians 10
• Subcutaneous regular insulin has a duration of action of 6-8 hours after injection, as reported by the American Academy of Family Physicians 10

Clinical Implications for Transition

• Subcutaneous insulin must be administered 1-2 hours before discontinuing the insulin drip to ensure adequate overlap and prevent rebound hyperglycemia, as recommended by The Lancet Diabetes and Endocrinology 11
• Patients should have stable glucose measurements for at least 4-6 hours consecutively before considering transition from continuous insulin infusion, according to The Lancet Diabetes and Endocrinology 11
• The transition dose can be estimated from the average insulin infusion rate during the 12 hours before transition, as suggested by The Lancet Diabetes and Endocrinology 11

Subcutaneous Regular Insulin Duration

• The onset of subcutaneous regular insulin is 15 minutes to 1.2 hours, as reported by the American Academy of Family Physicians 10
• The peak effect of subcutaneous regular insulin is 3-4 hours, with a range of 2-5.7 hours, according to the American Academy of Family Physicians 10
• The duration of subcutaneous regular insulin is 6-8 hours, though some studies show effects lasting up to 16 hours, as noted by the American Academy of Family Physicians 10

Common Pitfalls to Avoid

• Never discontinue IV insulin without prior subcutaneous dosing, especially in patients with type 1 diabetes or DKA, as this can precipitate rapid metabolic decompensation, as warned by The Lancet Diabetes and Endocrinology 11
• Do not use sliding scale insulin alone during transition; a basal-bolus regimen is required for adequate glycemic control, as recommended by The Lancet Diabetes and Endocrinology 11
• Account for the patient's nutritional status when calculating transition doses, as insulin requirements differ significantly between NPO, enteral, and oral feeding states, according to Diabetes Care 12

Insulin Administration Guidelines

Understanding Insulin Pharmacokinetics and Correction Dosing

• The American Diabetes Association guidelines assume a basal-bolus regimen for correction dosing, not waiting for NPH to take effect 13
• If glucose remains >13.9 mmol/L (250 mg/dL) at 4-6 hours post-NPH, then consider adding correction insulin, as recommended by The Lancet Diabetes and Endocrinology 14
• Administering rapid-acting insulin when NPH is nearing its peak effect creates a dangerous "stacking" scenario, significantly increasing hypoglycemia risk, and sliding scale insulin alone is strongly discouraged in hospitalized patients, as stated in Diabetes Care 13
• Correction insulin should be given immediately if glucose is >16.7-19.4 mmol/L (300-350 mg/dL) with symptoms of hyperglycemia or catabolic features, according to Annals of Internal Medicine 15

Insulin Dosing Guidelines for Hyperglycemia

Correction Insulin Dosing

• For patients with risk factors for hypoglycemia, such as age >65 years, renal failure, or poor oral intake, the maximum dose of regular insulin should be reduced 16

Critical Considerations Before Dosing

• If diabetic ketoacidosis (DKA) is present, continuous intravenous insulin infusion is preferred over subcutaneous dosing, according to the American Diabetes Association 16, 17
• For insulin-naive patients with blood glucose >300 mg/dL, a basal-plus regimen is recommended rather than correction insulin alone, with an initial total daily dose of 0.3-0.5 units/kg, as suggested by the American Diabetes Association 16, 18

Common Pitfalls to Avoid

• Sliding-scale insulin alone is strongly discouraged and associated with poor glycemic control, and a basal-plus or basal-bolus regimen is required for adequate glycemic control, according to the American Diabetes Association 16, 17
• Patients already on home insulin doses ≥0.6 units/kg/day should have a 20% reduction in total daily dose during hospitalization to prevent hypoglycemia, as recommended by the Endocrine Society 16

Transition to Scheduled Insulin Therapy

• Total daily insulin needs can be calculated based on 0.4 units/kg (or 0.3 units/kg if high hypoglycemia risk), with 50% as basal insulin and 50% as prandial insulin across three meals, as suggested by the American Diabetes Association 16, 18

Insulin Therapy for Hyperglycemia in Hospitalized Patients

Insulin Initiation Threshold and Target Range

• The American Diabetes Association recommends initiating insulin therapy when blood glucose persistently exceeds 180 mg/dL, with a target glucose range of 140-180 mg/dL for most critically ill and noncritically ill hospitalized patients 19, 20, 21
• More stringent goals of 110-140 mg/dL may be appropriate for selected patients, such as critically ill postsurgical patients, as long as they can be achieved without significant hypoglycemia 19, 20
• For noncritically ill patients, a target range of 100-180 mg/dL is recommended 19, 20
• The NICE-SUGAR trial demonstrated that intensive glycemic control (80-110 mg/dL) resulted in significantly higher mortality and 10- to 15-fold greater rates of hypoglycemia compared to moderate targets 19, 20

Monitoring Requirements

• The American Diabetes Association recommends point-of-care glucose monitoring before meals for patients who are eating, and every 4-6 hours for those not eating 19, 20
• More frequent monitoring ranging from every 30 minutes to every 2 hours is required for safe use of intravenous insulin 19, 20

Insulin Infusion Guidelines for Severe Hyperglycemia in Adults

Initiation and Patient Selection

• The American College of Critical Care Medicine recommends initiating continuous regular insulin at 0.1 units/kg/hour after excluding hypokalemia, targeting blood glucose between 140-180 mg/dL for most critically ill patients 22, 23
• Start IV insulin infusion when blood glucose persistently exceeds 180 mg/dL on two consecutive measurements, applicable to most critically ill populations including medical, surgical, cardiac, and neurologic ICU patients 22, 23
• The trigger threshold (≥180 mg/dL) is intentionally lower than the target range to prevent prolonged periods above goal 23
• Persistent hyperglycemia ≥180 mg/dL causes osmotic diuresis, endothelial glycocalyx dysfunction, and inflammation 22
• Avoid initiating insulin if serum potassium is <3.3 mEq/L; correct hypokalemia first, as recommended by the American Diabetes Association 24

Standard Dosing Protocol

• Initial insulin infusion rate: 0.1 units/kg/hour of regular insulin via continuous IV infusion, as recommended by the American Diabetes Association 24
• For DKA or severe hyperglycemia (>300 mg/dL): Consider IV bolus of 0.15 units/kg before starting the infusion, according to the American Diabetes Association 24
• For non-DKA hyperglycemia: Loading dose is optional and not universally recommended, as stated by the Society of Critical Care Medicine 22, 23

Target Blood Glucose Range

• Maintain blood glucose between 140-180 mg/dL for most critically ill adults, as recommended by the Society of Critical Care Medicine 22, 23, 25
• Avoid intensive targets (80-139 mg/dL) as they increase mortality and severe hypoglycemia risk 4-fold without improving outcomes, according to the Society of Critical Care Medicine 22, 23
• More stringent goals of 110-140 mg/dL may be considered only for select cardiac surgery patients if achievable without hypoglycemia, as recommended by the American Diabetes Association 26, 25

Monitoring Requirements

• Measure blood glucose every 1-2 hours during insulin infusion until stable, then every 2 hours, as recommended by the American Diabetes Association 26, 23
• The 2024 Society of Critical Care Medicine guidelines recommend frequent monitoring (≤1 hour intervals) or continuous glucose monitoring when available 22, 23
• Monitor serum potassium, as insulin drives potassium intracellularly; maintain K+ >3.3 mEq/L, according to the American Diabetes Association 24

Protocol-Driven Care

• Use explicit computerized decision support tools or validated paper protocols to guide insulin titration, as recommended by the Society of Critical Care Medicine 22, 23
• Protocols must demonstrate low hypoglycemia rates in validation studies before implementation, according to the Society of Critical Care Medicine 22, 23

Common Pitfalls to Avoid

• Do not use subcutaneous insulin in critically ill patients, particularly during hypotension or shock, as recommended by the American Diabetes Association 26
• Avoid sliding scale insulin as the sole regimen—it results in unacceptable glycemic variability and increased complications, according to the American Diabetes Association 26
• Do not target glucose <140 mg/dL in unselected critically ill patients—this increases mortality and severe hypoglycemia without benefit, as stated by the Society of Critical Care Medicine 22, 23

Correction Insulin Dosing Thresholds in Hospitalized Adults

General Threshold for Non‑Critically Ill Patients

Adjusted Thresholds for High‑Risk Populations

Safety Considerations for High‑Risk Patients

Hospitalized Patient Glycemic Management Guidelines

Definitions and Diagnostic Thresholds

• Hospital hyperglycemia is defined as a blood glucose concentration > 140 mg/dL (7.8 mmol/L). 28, 29
• Persistent glucose > 180 mg/dL on two consecutive measurements mandates initiation of insulin therapy. 28, 29, 30
• An admission HbA1c ≥ 6.5 % (48 mmol/mol) indicates that diabetes preceded the current hospitalization. 29
• Hypoglycemia levels:
  
  • Level 1 – glucose 54–70 mg/dL (3.0–3.9 mmol/L) requiring immediate intervention. 28
  • Level 2 – glucose < 54 mg/dL (3.0 mmol/L) associated with neuroglycopenic symptoms. 28
  • Level 3 – clinical event with altered mental/physical status needing assistance for recovery. 28

Glycemic Targets by Clinical Context

Critically Ill (ICU) Patients

• Start continuous IV insulin when glucose ≥ 180 mg/dL on two consecutive readings, irrespective of prior diabetes status. 28, 31
• Target glucose range 140–180 mg/dL for the majority of ICU patients. 28, 29, 30, 31
• More stringent targets (110–140 mg/dL) may be considered only for selected post‑cardiac surgery patients and only if achieved without significant hypoglycemia. 28, 29, 30
• Targets < 110 mg/dL should be avoided; the NICE‑SUGAR trial showed intensive control (80–110 mg/dL) increased mortality and severe hypoglycemia 10–15‑fold versus moderate targets. 28, 30

Non‑ICU (General Ward) Patients

• Target glucose 100–180 mg/dL for patients with new‑onset hyperglycemia or known diabetes. 28
• Pre‑prandial glucose < 140 mg/dL. 32, 29
• Random/post‑prandial glucose < 180 mg/dL. 32, 29
• Fasting glucose < 100 mg/dL predicts hypoglycemia within the next 24 hours. 28

Special Populations

• Patients with limited life expectancy may tolerate glucose > 250 mg/dL (13.9 mmol/L) to reduce osmotic diuresis, dehydration, and electrolyte disturbances. 28, 30
• Patients with severe comorbidities where frequent monitoring is impractical may accept glucose 180–250 mg/dL. 30

Insulin Therapy Strategies

ICU – Continuous Intravenous Insulin (Preferred Method)

• Recommended initial infusion rate: 0.1 U/kg/h of regular insulin; the short half‑life (<15 min) permits rapid titration. 33, 31
• Glucose monitoring every 1–2 hours during the initial phase, then every 2 hours after stabilization. 28, 31
• Use validated insulin protocols (paper‑based or computerized) that have demonstrated low hypoglycemia rates in validation studies. 28, 29, 31
• Computerized decision‑support algorithms improve glycemic control and reduce hypoglycemia compared with non‑structured protocols. 33, 31
• Subcutaneous insulin must not be used in critically ill patients, especially during hypotension or shock, because absorption is unpredictable. 33, 31

Non‑ICU – Basal‑Bolus Subcutaneous Regimen (Preferred Method)

• Initial total daily dose (TDD) ≈ 0.3 U/kg for patients with adequate oral intake; split 50 % basal (once daily long‑acting insulin) and 50 % prandial (rapid‑acting insulin before meals). 33, 31
• For patients with poor oral intake, a basal‑plus regimen (basal insulin plus a sliding‑scale correction) is effective for achieving control and preventing complications. 33, 31

Glucose Monitoring Frequency and Methods

• Eating patients: pre‑prandial glucose measurement before each meal. 29
• NPO patients: glucose measured every 4–6 hours. 29
• Patients on IV insulin: every 1–2 hours initially, then every 2 hours after stabilization. 28, 31
• Capillary point‑of‑care glucose testing is the standard method; arterial samples are preferred when available in critically ill patients. 29
• Continuous glucose monitoring (CGM) identifies more hypoglycemic events but is not yet recommended for routine use pending further safety and efficacy data. 29

Implementation of Institutional Support Systems

• Structured electronic insulin order sets with built‑in decision support improve average glucose levels without increasing hypoglycemia rates. 29, 30
• Consultation with a dedicated diabetes care team reduces hospital length of stay, improves glycemic control, and lowers readmission rates. 29